Slc2a4 Knockout cell line (CHO-K1)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

Slc2a4 (solute carrier family 2, facilitated glucose transporter, member 4) encodes a facilitated glucose transporter that enables glucose entry into cells in response to insulin. It contributes to glucose uptake and is involved in processes including brown fat cell differentiation, amylopectin biosynthesis, and cellular responses to tumor necrosis factor. Slc2a4 is associated with intracellular vesicles and the sarcolemma and is expressed in adipose tissue and several other organ systems. Its human ortholog is implicated in type 2 diabetes mellitus.

The CHO-K1 cell line was derived as a distinct karyotypic subclone from the parental CHO cell line, which was originally initiated by T. T. Puck in 1957 from an ovary biopsy of an adult Chinese hamster. Due to the absence of a critical gene in the proline biosynthetic pathway—specifically blocked at the step converting glutamic acid to glutamine $gamma$ semialdehyde—these cells strictly require exogenous proline supplementation for survival and growth. Additionally, CHO-K1 cells exhibit distinct morphological changes in response to cholera toxin, serving as a premier and robust host model globally utilized for recombinant protein expression, biopharmaceutical manufacturing, and genetic research.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.